Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

XALIA LEA- Xarelto for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) in Latin America, EMEA and Asia

NCT02210819 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02210819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02210819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
XALIA LEA- Xarelto for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) in Latin America, EMEA and Asia
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
June 27, 2014
Completion date
January 20, 2017
Enrollment
1,987 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

deep vein thrombosis (dvt), pulmonary embolism (pe)